Moderna个性化mRNA疫苗联合帕博利珠单抗显著降低黑色素瘤复发风险
Moderna mRNA vaccine almost halves the risk of skin cancer returning
Moderna与默克合作的个性化mRNA疫苗intismeran联合免疫治疗药物帕博利珠单抗,在III期临床试验中将中晚期黑色素瘤患者复发或死亡风险降低42%,共纳入1137例患者,随访约25个月未出现主要不良反应。该疫苗通过测序患者肿瘤DNA识别突变产生的新抗原进行定制,专为术后有复发风险且对单药免疫治疗反应不佳的患者设计,长期生存获益仍需进一步观察。
III期个性化mRNA疫苗联合免疫治疗降低黑色素瘤复发风险,原文提供了随访数据与安全性信息。

Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer.Credit: Olga Pankova/Getty
A personalized mRNA vaccine reduced the risk of skin cancer returning or the recipient dying by 42% when used alongside an immunotherapy drug, according to long-awaited results for what could become the first approved mRNA vaccine for cancer.
Oncologists regard a risk reduction of 10% as substantial, says Kristen Radford, an immunotherapist at Mater Research in Brisbane. A more than 40% risk reduction “would send many researchers over the Moon”, adds Seth Cheetham, a geneticist at the University of Queensland in Brisbane, Australia.
The personalized vaccine, called intismeran, is not designed to prevent skin cancer, or melanoma, from developing in the first place, but to stop it returning in people who have already undergone surgery to remove tumours.
Anticipation for the trial results has been building since August, when the vaccine’s developers — Merck, based in Rahway, New Jersey, and Moderna, which is headquartered in Cambridge, Massachusetts — announced early positive results. Data from the phase III trial will be presented at the European Society for Medical Oncology meeting in Madrid on 24 October. But when data were leaked online on 22 October, the companies released the key results.
The stock price for Moderna, a pioneer in mRNA vaccine technology, had been rising since the August announcement, but dropped by around 25% after the leak. Health-care financial analyst Evan Seigerman at BMO Capital Markets in New York City told media company Forbes that such reactions in the stock market probably reflect “inflated expectation into the full data release, rather than a true indictment on the efficacy of the combo therapy”.
Chance of survival
The intismeran trial enrolled 1,137 people with moderate to advanced melanoma across 157 centres. Participants were randomly assigned to receive a tailor made vaccine (intismeran) alongside the immunotherapy drug pembrolizumab — which is already used to treat melanoma — or pembrolizumab plus an inactive placebo. Trial leader Georgina Long, an oncologist at Melanoma Institute Australia in Sydney, says participants have so far been followed for around 25 months and will continue to be monitored for several years to determine whether the vaccine improves overall survival. She adds that the therapy did not result in any major harmful side effects.
Roughly 15 years ago, people with advanced melanoma typically survived for only months. Today, nearly 55% are effectively cured with targeted drugs or immunotherapies, says Long. The combination of intismeran and pembrolizumab is designed for people whose cancer could return after surgery and who do not respond to immunotherapy alone, she says.
Jessamy Tiffen, a cancer geneticist at the Centenary Institute in Sydney, says that the trial results are exciting, but only time will tell how effective the treatment is beyond two years. “Cancer cells also have an insidious ability to adapt and evade whatever treatment we throw at them,” she says. Furthermore, some people did not respond to the vaccine, she says.
Long says that her team will conduct a statistical analysis to identify who is most likely to benefit from the treatment.
Challenging to make
To develop intismeran, Long and her colleagues sequenced DNA from a sample of each participant’s tumour to identify mutations in the cancer cells. These mutations can give rise to proteins called neoantigens, which help to distinguish cancer cells from healthy ones.
来源:Nature 综合主刊 · nature.com